Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Momentum 2.1/10 is below the 5.0 floor at $315.83 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Leverage penalty (D/E 3.8): -1.5; Concentration risk — Product: AMVUTTRA.
Alnylam Pharmaceuticals develops and commercializes RNAi therapeutics, with six approved medicines led by AMVUTTRA (vutrisiran, including cardiomyopathy approval in March 2025). The company generated .99 billion in net product revenues in 2025, its first profitable year;... Read more
Sell if holding. Momentum 2.1/10 is below the 5.0 floor at $315.83 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Leverage penalty (D/E 3.8): -1.5; Concentration risk — Product: AMVUTTRA. Chart setup: RSI 47 mid-range, Bollinger mid-band. Score 6.0/10, moderate confidence.
Passes 5/6 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity no date, semi cycle peak clear). Fails on weak momentum. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductAMVUTTRA10-K Item 1A: 'In 2025, a significant portion of our net product revenues was derived from the sale of our TTR products, and in particular AMVUTTRA for the treatment of ATTR-CM'
Material Events(8-K, last 90d)
- 2026-03-04Item 5.02LOWOn March 2, 2026, the Board granted a special equity award to CEO Yvonne Greenstreet under the 2018 Stock Incentive Plan, recognizing her leadership including ~100% stockholder return and the 2025 FDA approval of AMVUTTRA for TTR cardiomyopathy. Routine compensatory arrangement; no departure or appointment.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker·1 ceiling hit
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 2.1/10 is below the 5.0 floor at $315.83 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Leverage penalty (D/E 3.8): -1.5; Concentration risk — Product: AMVUTTRA. Chart setup: RSI 47 mid-range, Bollinger mid-band. Prior stop was $294.23. Score 6.0/10, moderate confidence.
Take-profit target: $404.21 (+27.8% upside). Prior stop was $294.23. Stop-loss: $294.23.
Concentration risk — Product: AMVUTTRA; Leverage penalty (D/E 3.8): -1.5; Negative momentum.
Alnylam Pharmaceuticals, Inc. trades at a P/E of 129.8 (forward 21.4). TrendMatrix value score: 5.5/10. Verdict: Sell.
36 analysts cover ALNY with a consensus score of 3.9/5. Average price target: $449.
What does Alnylam Pharmaceuticals, Inc. do?Alnylam Pharmaceuticals develops and commercializes RNAi therapeutics, with six approved medicines led by AMVUTTRA...
Alnylam Pharmaceuticals develops and commercializes RNAi therapeutics, with six approved medicines led by AMVUTTRA (vutrisiran, including cardiomyopathy approval in March 2025). The company generated .99 billion in net product revenues in 2025, its first profitable year; royalties from Novartis's Leqvio and Sanofi's Qfitlia provide additional revenue under RNAi licenses.